ELLIPSES
LIVE

Serial Number

90886631

Owner

Ellipses Pharma Ltd

Attorney

John C. Cain

Filing Date

Aug 17, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ELLIPSES Trademark

Serial Number: 90886631 • Registration: 7971817

ELLIPSES is a trademark filed by Ellipses Pharma Ltd on August 17, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Ellipses Pharma Ltd (2 trademarks)

Berkeley Square House
London W1J6BD , GB

Entity Type: 99

Trademark Details

Filing Date

August 17, 2021

Registration Date

October 7, 2025

Published for Opposition

August 19, 2025

Goods & Services

Pharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer; dietetic preparations for medical purposes; dietetic foods for use in clinical nutrition; food supplements; nutraceuticals for therapeutic and medical purposes; medicated food supplements; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs being preparations; compounds for treating cancer being pharmaceutical preparations; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer

Medical and pharmacological research services; biological research; clinical research in the field of oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and surgery in relation to cancer; medical research; providing an online network environment for research and development for drug and pharmaceutical development; providing an online network environment for the design, development and testing of drugs and pharmaceuticals; Providing scientific and technological services and research, analysis, and design relating thereto; design, development and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research; expert advice relating to drug development, being consulting services in the field of pharmaceutical research; laboratory analysis in the field of pharmaceutical research; computer hardware and software design and development in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; computer network services in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software hosting services in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software as a service in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; Information Technology (IT) consultancy, advisory and information services relating to a network of medical research professionals; scientific advisory services; scientific research projects and studies being scientific research and development; conducting clinical trials being scientific and medical research for others; scientific and medical clinical research for others; clinical research for cancer treatments and pharmaceuticals; providing an online network environment for clinical trials; conducting and collating a research network for treatment, cure and prevention of cancer being medical and scientific research; development of measuring and testing methods being research and development in the field of pharmaceuticals; quality control of services; evaluation of drug development services; industrial testing, namely, industrial design services; pharmaceutical product evaluation; testing of chemicals

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 7, 2025 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 3, 2025 NRCC
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 10, 2025 CNSA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
May 14, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 14, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 14, 2025 REAP
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 6, 2025 RCCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 21, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 21, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 21, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 21, 2024 REAP
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 8, 2024 RCCK
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 7, 2024 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 29, 2023 RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 8, 2023 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 25, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 25, 2022 GNSL
SUSPENSION LETTER WRITTEN
Nov 25, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 23, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 23, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 23, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 23, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 23, 2022 CNRT
ASSIGNED TO EXAMINER
May 18, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 5, 2021 NWOS
NEW APPLICATION ENTERED
Aug 20, 2021 NWAP